Daily salbutamol in young patients with SMA type II.

  title={Daily salbutamol in young patients with SMA type II.},
  author={Marika Pane and Susanna Staccioli and Sonia Messina and Adele D'amico and Marco Pelliccioni and Elena Stacy Mazzone and Marina Cuttini and Paolo Alfieri and Roberta Battini and Marion Main and Francesco Muntoni and Enrico Bertini and Marcello Villanova and Eugenio Mercuri},
  journal={Neuromuscular disorders : NMD},
  volume={18 7},
The aim of this open pilot study was to establish the profile of tolerability and clinical response of salbutamol (albuterol) in a cohort of young children affected by type II spinal muscular atrophy (SMA). Twenty-three children between 30 months and 6 years of age were treated with salbutamol (2 mg three times a day) for 1 year. All children were longitudinally assessed using the Hammersmith motor functional scale 6 months before treatment started (T0), at baseline (T1) and 6 and 12 months… CONTINUE READING
31 Citations
20 References
Similar Papers


Publications citing this paper.
Showing 1-10 of 31 extracted citations


Publications referenced by this paper.
Showing 1-10 of 20 references

StataCorp.2005. Stata statistical software: Release 9.0. College Station, TX: StataCorp

  • M. Pane
  • Neuromuscular Disorders
  • 2008
1 Excerpt

Similar Papers

Loading similar papers…